INMD Jan 2024 45.000 call

OPR - OPR Delayed Price. Currency in USD
1.3500
-0.1500 (-10.00%)
As of 01:13PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close1.5000
Open1.3500
Bid1.3500
Ask1.6500
Strike45.00
Expiry date2024-01-19
Day's range1.3500 - 1.3500
Contract rangeN/A
Volume1
Open interest745
  • Zacks

    Solid Earnings Fuel Potential Bull Market in Medical Devices

    CNBC's Jim Cramer predicts a booming bull market for medical devices, with positive earnings reports across the space. INMD, JNJ, ISRG and GEHC can emerge as potential winners.

  • Motley Fool

    3 Exceptional Growth Stocks You Can Buy With $200 Right Now

    Have you noticed growth stocks are making a comeback? The Vanguard Growth ETF, which contains heaps of growth stocks, is up 21% this year. If you've been investing in growth stocks for a while you probably remember they started soaring last summer and then lost all those gains by the end of 2022.

  • Motley Fool

    Is This the Best Healthcare Stock to Buy Right Now?

    It's not easy to find that combination given the current economic conditions, but one that could fit the bill is InMode (NASDAQ: INMD). With U.S. economic growth slowing, many fast-growing businesses have been laying off staff to cut costs after previously overestimating their growth opportunities. InMode, however, is still firing on all cylinders.

  • Motley Fool

    More Likely to 5X First: Teladoc vs. InMode

    Teladoc Health (NYSE: TDOC) and InMode (NASDAQ: INMD) both operate in high-growth industries. Teladoc is a leader in telemedicine. InMode specializes in selling devices in the minimally invasive and non-invasive aesthetics market.

  • Motley Fool

    2 Magnificent Growth Stocks You Can Buy With $150 Right Now

    Over the past few years, new investors have learned the hard way that investing in growth stocks can be highly unpredictable. You may remember the Nasdaq Composite, which contains heaps of growth stocks, rose 21% in 2021, only to collapse 33% in 2022. Giant market swings like the one recently experienced may lead you to believe that growth stock investing is an endeavor only suited to Wall Street professionals, but this is not the case.

  • Motley Fool

    1 Soaring Growth Stock That's Still an Unbeatable Bargain

    This company's minimally invasive alternative to liposuction surgery isn't getting the attention it deserves.

  • Zacks

    Wall Street Analysts Think InMode (INMD) Could Surge 45.95%: Read This Before Placing a Bet

    The average of price targets set by Wall Street analysts indicates a potential upside of 46% in InMode (INMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • Motley Fool

    Why InMode Stock Plummeted by 10% on Tuesday

    What happened The stock of medical aesthetics tech company InMode (NASDAQ: INMD) wasn't looking very pretty on Tuesday. The company published its latest set of quarterly figures, and some investors found them sorely wanting.

  • Motley Fool

    InMode (INMD) Q1 2023 Earnings Call Transcript

    Image source: The Motley Fool. InMode (NASDAQ: INMD)Q1 2023 Earnings CallMay 02, 2023, 8:30 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and welcome to the InMode first quarter 2023 financial results conference call.

  • Zacks

    InMode (INMD) Q1 Earnings and Revenues Top Estimates

    InMode (INMD) delivered earnings and revenue surprises of 4% and 0.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • Zacks

    Bio-Rad Laboratories (BIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    Bio-Rad (BIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Zacks

    InMode (INMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    InMode (INMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Motley Fool

    3 Healthcare Stocks That Could Help Make You a Fortune

    When you think of healthcare stocks, you may think of steady growth and security. Let's check out three healthcare companies that fit the bill. In fact, if all goes well, Vertex may launch a new CF treatment in the not-too-distant future.

  • Motley Fool

    3 Exceptional Growth Stocks You Can Buy Now With $200 and Hold Forever

    If you've paid any attention to the stock market over the past few years, you know that growth-stock investing can be wildly unpredictable. You probably remember the Nasdaq Composite index, which houses a lot of growth stocks, briefly tanked at the outset of the COVID-19 pandemic in 2020. Assuming your emergency fund is topped off and you have all your bills paid, just $200 is enough to buy one share of each of these top growth stocks.

  • Zacks

    Wall Street Analysts Believe InMode (INMD) Could Rally 33.66%: Here's is How to Trade

    The consensus price target hints at a 33.7% upside potential for InMode (INMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • Motley Fool

    5 Top Growth Stocks to Buy Before the Next Bull Market

    It's never too early to start planning for the next bull market. Those days of market gains and optimism will be back. History tells us so -- bull markets always have followed bear markets. So, how should you prepare? By taking advantage of the low prices a down market offers us and buying quality companies that could win over time.

  • Motley Fool

    Could These 2 Growth Stocks Outperform Amazon in 2023?

    Despite being one of the world's largest, most steadily growing businesses, Amazon's (NASDAQ: AMZN) stock fell by around 40% in the last 12 months, leaving investors looking for alternatives to buy for growth. At the same time, analysts anticipate that lesser-known growth stocks like InMode (NASDAQ: INMD) and Green Thumb Industries (OTC: GTBIF) will see their shares climb by 63% and 152%, respectively, which would mean they'd blow Amazon out of the water.

  • Motley Fool

    Got $100? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond

    Teladoc specializes in virtual medical visits and sells its plans to companies and organizations. Teladoc also sells its BetterHelp mental health online consultations directly to consumers. What's weighed on the stock is the fact that Teladoc hasn't yet turned that revenue into profit.

  • Motley Fool

    2 Exceptional Growth Stocks That Could Jump 37.6% to 40.2% Higher, According to Wall Street

    These businesses are at the top of their respective industries, but you wouldn't know it by looking at their stock prices.

  • Motley Fool

    Don't Miss Out on These 2 Undervalued Stocks With Huge Growth Potential

    The market doesn't always get a growth stock's valuation right, and when it's wrong, there's often an opportunity to make a hearty dollop of dosh -- and it's always good to feel as if you're a step ahead of the market. On that note, two growth stocks look favorably priced right now, and there's good reason to think they'll keep growing in the years ahead. Israeli medical aesthetics company InMode (NASDAQ: INMD) is a stellar investment opportunity thanks to its slightly cheap shares and its finely tuned growth engine.

  • Motley Fool

    2 High-Growth Stocks That Could Double Your Money in 5 Years or Less

    Wall Street analysts are expecting that 23andMe's (NASDAQ: ME) stock will hit around $5.69 within a year, which means they think it can grow to more than double its current price of $2.61. In 2019, it reported sales of $156.3 million, which means that its compound annual growth rate (CAGR) from 2019 through 2024 would be 31.3%.

  • Motley Fool

    Get Ready to Soar: 2 High-Octane Growth Stocks Wall Street Expects to Climb in 2023

    Wall Street analysts aren't always right with their predictions about stocks, but they typically have a strong argument for why they think a given outcome is going to happen. On that note, let's evaluate a couple of growth stocks that Wall Street has high hopes for to see if they might be a good fit for your portfolio. When it comes to businesses making medical aesthetics treatments that are alternatives to plastic surgeries and face lifts, InMode (NASDAQ: INMD) is a leader.

  • Motley Fool

    2 Terrific Growth Stocks to Buy With $200 Right Now

    Last year, investors learned the hard way that growth stock investing can be unpredictable. The Nasdaq Composite index, which contains heaps of growth stocks, collapsed by 33% in 2022. One recurring theme for bear markets like the one we've experienced is that they've always been temporary.

  • Motley Fool

    Better Medtech Stock to Buy: InMode or Outset Medical?

    Take medical technology (or medtech) stocks, for example. Both InMode (NASDAQ: INMD) and Outset Medical (NASDAQ: OM) reported their fourth-quarter results this week. Which is the better medtech stock to buy?

  • Motley Fool

    InMode (INMD) Q4 2022 Earnings Call Transcript

    Before we begin, I would like to remind our listeners that certain information provided on this call may contain forward-looking statements and that the safe harbor statement outlined in today's earnings release also pertains to this call. Changes in business, competitive, technological, regulatory, and other factors could cause actual results to differ materially from those expressed by the forward-looking statements made today. As such, we can give no assurance as to the accuracy of our forward-looking statements and assume no obligation to update them, except as required by law.